Vera Therapeutics, Inc. (NASDAQ:VERA) Director Sells $3,580,597.80 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Maha Katabi sold 81,009 shares of the business’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $44.20, for a total transaction of $3,580,597.80. Following the completion of the sale, the director now owns 3,547,437 shares in the company, valued at $156,796,715.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Maha Katabi also recently made the following trade(s):

• On Monday, March 25th, Maha Katabi sold 340,000 shares of Vera Therapeutics stock. The shares were sold at an average price of $40.50, for a total transaction of $13,770,000.00.
• On Tuesday, January 30th, Maha Katabi bought 161,290 shares of Vera Therapeutics stock. The stock was purchased at an average price of $31.00 per share, for a total transaction of $4,999,990.00.

Vera Therapeutics Stock Performance

VERA stock opened at $43.83 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.97 and a current ratio of 6.97. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -19.14 and a beta of 1.10. Vera Therapeutics, Inc. has a 1 year low of $5.95 and a 1 year high of $50.78. The stock’s fifty day moving average is $39.76 and its two-hundred day moving average is $22.93.

Analyst Upgrades and Downgrades

VERA has been the subject of a number of research analyst reports. Raymond James raised shares of Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $29.00 to $37.00 in a research report on Friday, January 26th. Oppenheimer initiated coverage on shares of Vera Therapeutics in a research report on Thursday, January 25th. They issued an “outperform” rating and a $26.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Vera Therapeutics in a research report on Wednesday, December 27th. JPMorgan Chase & Co. lowered their price objective on shares of Vera Therapeutics from $25.00 to $22.00 and set an “overweight” rating for the company in a research report on Thursday, November 30th. Finally, Cantor Fitzgerald assumed coverage on shares of Vera Therapeutics in a research report on Monday, January 8th. They issued an “overweight” rating for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $32.29.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of VERA. Commodore Capital LP increased its holdings in shares of Vera Therapeutics by 93.0% during the second quarter. Commodore Capital LP now owns 5,450,000 shares of the company’s stock valued at $87,472,000 after purchasing an additional 2,625,971 shares during the period. FMR LLC increased its holdings in shares of Vera Therapeutics by 39.7% during the first quarter. FMR LLC now owns 5,796,259 shares of the company’s stock valued at $44,979,000 after purchasing an additional 1,647,613 shares during the period. Schroder Investment Management Group acquired a new position in shares of Vera Therapeutics during the fourth quarter valued at $17,087,000. Point72 Asset Management L.P. acquired a new position in shares of Vera Therapeutics during the fourth quarter valued at $15,139,000. Finally, BlackRock Inc. increased its holdings in shares of Vera Therapeutics by 53.9% during the second quarter. BlackRock Inc. now owns 2,170,134 shares of the company’s stock valued at $34,831,000 after purchasing an additional 759,864 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis.